Advertisement

Topics

Latest "Biogen Incorporated" News Stories

19:07 EST 19th February 2018 | BioPortfolio

Here are the most relevant search results for "Biogen Incorporated" found in our extensive news archives from over 250 global news sources.

More Information about Biogen Incorporated on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Biogen Incorporated for you to read. Along with our medical data and news we also list Biogen Incorporated Clinical Trials, which are updated daily. BioPortfolio also has a large database of Biogen Incorporated Companies for you to search.

Showing "Biogen Incorporated" News Articles 1–25 of 493

Saturday 17th February 2018

Biogen (BIIB) Downgraded to "Hold" at BidaskClub

Other equities analysts have also issued reports about the company. Guggenheim initiated coverage on Biogen in a report on Monday, October 23rd.


Friday 16th February 2018

Biogen-Aktie: Ausblick verdunkelt sich!

New York - Biogen-Aktienanalyse von Analyst David Toung von Argus Research: Laut einer Aktienanalyse empfiehlt der Analyst David Toung von Argus Research die Aktien des US-Biotechkonzerns Biogen In...

Trial tinkering seen as bad sign for Biogen's aducanumab

A day after Merck & Co pulled the plug on its Phase III verubecestat program, alarm bells started ringing…


Biogen updates Phase III AD studies

Concerns mount over Biogen Alzheimer's drug

There are mounting concerns over Biogen’s Alzheimer’s drug aducanumab after the company announced tweaks to the design of ongoing phase 3 trials, as the FDA released new guidance designed to help pharma find more treatments after a string of failures...

Bio Roundup: Trump’s Budget, Biogen’s AD Reveal, Hugin’s Run & More

Another week of White House chaos and American gun violence. Amid it all, we tried to parse what the Trump administration’s 2019 budget proposal meant for the biomedical and life-science worlds. There was talk of tackling high drug prices in the budget document, but nothing to give Medicare direct negotiating power with drug companies or […]

Thursday 15th February 2018

Relevium Announces 2018 AGM Results

MONTREAL, QUEBEC -- (Marketwired) -- 02/16/18 -- Relevium Technologies Inc. (TSX VENTURE: RLV)(OTCQB: RLLVF)(FRANKFURT: 6BX) (the "Company" or "Relevium"), is pleased to announce the positive results from its annual and special meeting held on February 15, 2018 in Montreal, Canada (the "AGM"). Election of Directors The shareholders supported the appointment of the Board and the resolutions prop...

Biogen Spooks With Phase III Aducanumab Changes

Recruiting more patients into a trial to retain statistical power is standard practice, but with other companies discontinuing late-stage investigational...    

Biogen shares hit by key Alzheimer’s drug concerns

Biogen made investors very nervous after it announced that it was choosing to add an additional 510 patients to its key trial into its Alzheimer’s medicine. The decision to flood more patients into the trial was made after it apparently saw “increased variability” on the data from those receiving aducanumab. It’s a bad time for potential treatments into Alzheimer’s, with a raft of compan...

Biogen shares fall after unexpected 'variability' in Alzheimer's studies

Company executives insisted the pre-planned check did not change their confidence in aducanumab, which has become Biogen's key pipeline asset.

Bioverativ taps new manufacturer as it steps out of Biogen's shadow

The spinoff-turned-Sanofi-company could pay more than $100 million to Oxford BioMedica for lentiviral vector production.

Wednesday 14th February 2018

Biogen Plunges After Making Changes to Alzheimer's Drug Trial

The company says it’s adding patients to clarify trial results.

The New England Journal of Medicine Publishes SPINRAZA® (nusinersen) Phase 3 Study Results in Individuals with Later-Onset Spinal Muscular Atrophy

SPINRAZA demonstrated stabilization or improvement in motor function in individuals with spinal muscular atrophy (SMA) where the natural history of the disease is a decline in motor function over time The majority of individuals treated with SPINRAZA demonstrated benefits in upper limb and general motor function, including crawling ...

STAT Plus: Biogen’s share price falters on a surprise dose of ‘variability’ in Alzheimer’s trial

>@damiangarde tries to translate Biogen's surprise announcement on its Alzheimer’s program.

Biogen shares fall as it adds patients to Alzheimer’s medicine trials

Biogen slips on Phase III AD studies

AGTC Announces Sue Washer, CEO, Elected to Biotechnology Innovation Organization's Board of Director

AGTC Announces Sue Washer, CEO, Elected to Biotechnology Innovation Organization's Board of Directors   GAINESVILLE, Fla., and CAMBRIDGE, Mass., Feb. 14, 2018 -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology c

Another Alzheimer's bust as Merck stops verubecestat study

Late-stage BACE1 failure could be an ominous signal for Eli Lilly/AZ and Biogen/Eisai

Another Alzheimer's bust as Merck & Co stops verubecestat study

Late-stage BACE1 failure could be an ominous signal for Eli Lilly/AZ and Biogen/Eisai

FDA Grants Priority Review for Genentech’s Rituxan (Rituximab) for Pemphigus Vulgaris

Pemphigus vulgaris (PV) is a life-threatening, autoimmune condition with limited treatment options1 The FDA previously granted Breakthrough Therapy Designation and Orphan Drug Designation for Rituxan in PV Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food...

Tuesday 13th February 2018

Bioverativ Reports Fourth Quarter and Full Year 2017 Performance

Full year 2017 year-over-year revenues up 31.7% Fourth quarter revenues up 28.3% year-over-year Full year 2017 GAAP operating margin of 38.3%; Non-GAAP operating margin of 46.5% Full year cash flows from operations of $591 million Bioverativ Inc. (NASDAQ: BIVV) today reported financi...

Monday 12th February 2018

Horizon Discovery enters into license agreement with US immuno-oncology company.

Horizon out-licenses proprietary cell line and Helitron transposon gene editing technologies, demonstrating Horizon’s ability to generate revenues from internally derived IP Horizon retains commercial rights over improvements to its technology platforms to develop new cell line technologies and gene delivery IP that can be licensed to customers for applications in biomanufacturin...

Norway to buy Biogen's Spinraza medicine: broadcaster NRK

OSLO (Reuters) - Norwegian authorities will buy the rare-disease treatment Spinraza for patients from U.S. drugmaker Biogen Inc at a cost of 7 million Norwegian crowns ($880,381.33) per year per patient, public broadcaster NRK reported on Monday.

Friday 9th February 2018

Biogen reveals Tysabri failure in stroke trial

Biogen has confirmed that it will not pursue further development of Tysabri in acute ischemic stroke (AIS) after a mid-stage study missed primary and secondary efficacy goals.

20152023 World Biopharma Market Research Report by Product Type, EndUser / Application and Regions / Countries [Report Updated: 25012018] Prices from USD $2800

SummaryThis report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions.Market Segment as follows:By Region / Countries North America U.S., Canada, Mexico Europe Germany, U.K., France, Italy, Russia, Spain etc South Americ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks